FAST NEWS: Zai Lab’s loss narrows on improved drug sales
The Latest: Biotech company Zai Lab Ltd. (9688.HK; ZLAB.US) reported Wednesday that its loss narrowed 33.7% to $80.3 million in the second quarter of this year. Looking Up: The company's net product revenue for…
China-focused Tigermed staves off biopharma gloom
Investors have not been deterred by an earnings slide, wagering that the drugs services company is better placed to weather an industry storm than some biopharma stocks Key Takeaways: Tigermed…
FAST NEWS: Zai Lab’s loss narrows on strengthening sales
The latest: Biotech company Zai Lab Ltd. (9688.HK; ZLAB.US) reported Wednesday that its loss narrowed 24.5% to $335 million last year. Looking up: The narrower loss owed mainly to a 25% increase in revenue…
Junshi hopes new scientist CEO can cure its woes
The biotech company has been dogged by multiple challenges recently, including declining revenue, ongoing losses and a recent rejection by one of its overseas partners Key Takeaways: Junshi has appointed…
FAST NEWS: Zai Lab’s loss narrows on growing revenue
The latest: Biotech company Zai Lab Ltd. (9688.HK; ZLAB.US) announced Wednesday that its loss narrowed 57% to $69.15 million in the third quarter from $161 million a year earlier. Looking up: The…
FAST NEWS: U.S. investment firm boosts WuXi AppTec stake
The latest: The Capital Group, a U.S. asset manager, disclosed it purchase 2.52 million Hong Kong-listed shares of WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) for HK$177 million ($20.8 million), raising…
BeiGene goes for global growth with sales and R&D push
The maker of cancer drugs is ploughing most of its rising revenues into research and sales, as it prioritizes expansion over profits for now Key Takeaways: BeiGene’s revenue in the…
